I am only quoting what the RCS has said. My hon. Friend might want to decry my statement, but the RCS’s overall conclusion on the merits of the Bill is a different issue. I am merely pointing out that it has stated that this could be a consequence of the Bill. People can draw their own conclusions from that. I would like to think that I have tried to be as even-handed as possible by outlining the potential benefits of the Bill as well as the other potential consequences. I have quoted organisations that have raised concerns. I am trying to be even-handed, whether my hon. Friend likes it or not—I suspect that she does not—and that is what the Royal College of Surgeons has said.
Access to Medical Treatments (Innovation) Bill
Proceeding contribution from
Philip Davies
(Conservative)
in the House of Commons on Friday, 16 October 2015.
It occurred during Debate on bills on Access to Medical Treatments (Innovation) Bill.
About this proceeding contribution
Reference
600 c583 Session
2015-16Chamber / Committee
House of Commons chamberLibrarians' tools
Timestamp
2021-11-04 13:31:31 +0000
URI
http://hansard.intranet.data.parliament.uk/Commons/2015-10-16/15101634000265
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2015-10-16/15101634000265
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2015-10-16/15101634000265